Treatment for Syndromes of Dementia and Movement Disorders Market (By Type: Movement Disorders, Progressive Dementia, and Progressive Dementia with Neurological Abnormalities; By Geography: North America, Europe, Asia-Pacific and RoW) Global Scenario, Market Size, Outlook, Trend, and Forecast, 2015-2024
Global Treatment for Syndromes of Dementia and Movement Disorders Market is estimated to reach $28.6 Billion by 2024; growing at a CAGR of 8.9% from 2016 to 2024. Dementia is loss of thinking capability or a collection of symptoms caused by disorders affecting brain. Dementia and movement disorders are majorly triggered due to damages caused to brain instigated by diseases or a series of strokes. As stated in World Alzheimer Report 2015, 46 million people have been affected by dementia and the number is anticipated to increase to 131.5 million by 2050. People above the age of 65 years are more likely to be affected by dementia and movement disorders. These disorders progress gradually and gets worse over the time. Diagnosis at early stage is very essential in order to ensure accurate diagnosing and treatment to the person.
Increasing geriatric population, growing prevalence of neurodegenerative disorders, increasing awareness among people, and availability of various healthcare services are the factors boosting the development of the global treatment for syndrome of dementia and movement disorders market. Moreover, various awareness programs and market expansion are likely to provide growth opportunities in the coming years. Nevertheless, long down-time for approval and lack of proper management of these disorders might hamper the development of the market.
The global treatment for syndromes of dementia and movement disorders market is bifurcated into type and geography. By type, the market is sub-segmented into movement disorders (Parkinson’s disease, progressive supranuclear palsy, multiple system atrophy, hallervorden-spatz disease and others), progressive dementia (Alzheimer’s disease, Lewy body dementia, frontotemporal dementia/pick and others) and progressive dementia with neurological abnormality (corticobasal ganglionic degeneration, Huntington’s disease, amyotrophic lateral sclerosis(ALS)).
By geography, the market has been bifurcated into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The U.S., Canada, and Mexico are covered under North America wherein Europe covers Germany, Italy, UK, France, Spain, and others. Asia-Pacific covers Japan, China, India, and others. RoW covers South America, Middle East, and Africa.
The key players in the market include Baxter International, Inc., Valeant Pharmaceutical International, Abbott Laboratories, Inc., AstraZeneca GmbH, AG, Merck & Co., Inc., Sanofi S.A., Novartis AS, F. Hoffmann-La Roche, Bristol-Myers Squibb, and Pfizer, Inc., among others.
The key takeaways from the report
Type Segments
Increasing geriatric population, growing prevalence of neurodegenerative disorders, increasing awareness among people, and availability of various healthcare services are the factors boosting the development of the global treatment for syndrome of dementia and movement disorders market. Moreover, various awareness programs and market expansion are likely to provide growth opportunities in the coming years. Nevertheless, long down-time for approval and lack of proper management of these disorders might hamper the development of the market.
The global treatment for syndromes of dementia and movement disorders market is bifurcated into type and geography. By type, the market is sub-segmented into movement disorders (Parkinson’s disease, progressive supranuclear palsy, multiple system atrophy, hallervorden-spatz disease and others), progressive dementia (Alzheimer’s disease, Lewy body dementia, frontotemporal dementia/pick and others) and progressive dementia with neurological abnormality (corticobasal ganglionic degeneration, Huntington’s disease, amyotrophic lateral sclerosis(ALS)).
By geography, the market has been bifurcated into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The U.S., Canada, and Mexico are covered under North America wherein Europe covers Germany, Italy, UK, France, Spain, and others. Asia-Pacific covers Japan, China, India, and others. RoW covers South America, Middle East, and Africa.
The key players in the market include Baxter International, Inc., Valeant Pharmaceutical International, Abbott Laboratories, Inc., AstraZeneca GmbH, AG, Merck & Co., Inc., Sanofi S.A., Novartis AS, F. Hoffmann-La Roche, Bristol-Myers Squibb, and Pfizer, Inc., among others.
The key takeaways from the report
- The report will provide a detailed analysis of Global Treatment for Syndromes of Dementia and Movement Disorders Market with respect to major segments such as type, and geography
- The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024
- Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
- An exhaustive regional analysis of Treatment for Syndromes of Dementia and Movement Disorders Market from 2015 to 2024 has been included in the report
- Profile of the key players in the Global Treatment for Syndromes of Dementia and Movement Disorders Market will be provided, which include key financials, product & services, new developments and business strategies
Type Segments
- Movement Disorders
- Parkinson’s Disease
- Progressive Supranuclear Palsy
- Multiple System Atrophy
- Hallervorden-Spatz Disease
- Others
- Progressive Dementia
- Alzheimer’s Disease
- Lewy Body Dementia
- Frontotemporal Dementia/Pick
- Others
- Progressive Dementia with Neurological Abnormality
- Corticobasal Ganglionic Degeneration
- Huntington’s Disease
- Amyotrophic Lateral Sclerosis (ALS)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- Italy
- UK
- France
- Spain
- Other
- Asia-Pacific
- Japan
- China
- India
- Others
- RoW
- South America
- Middle East
- Africa
CHAPTER 1 PREFIX
1.1 Market Scope
1.2 Report Description
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 In-house Data Modeling
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OUTLINE
3.1 Market Inclination, Trend, Outlook and Viewpoint
3.2 Market Share Analysis: Company’s Competitive Scenario
3.3 Value Chain Analysis
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Impact Analysis
3.4.2 Restraints
3.4.2.1 Impact Analysis
3.4.3 Opportunities
3.5 Porter’s five forces analysis
3.5.1 Factors Impact Analysis
CHAPTER 4 TREATMENT FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS MARKET BY TYPE: MARKET SIZE AND FORECAST, 2015 – 2024
4.1 Overview
4.2 Movement Disorders
4.2.1 Current Trend and Analysis
4.2.2 Market Size and Forecast
4.2.3 Parkinson’s Disease
4.2.4 Progressive Supranuclear Palsy
4.2.4 Multiple System Atrophy
4.2.6 Hallervorden-Spatz Disease
4.2.7 Others
4.3 Progressive Dementia
4.3.1 Current Trend and Analysis
4.3.2 Market Size and Forecast
4.3.3 Alzheimer’s Disease
4.3.4 Lewy Body Dementia
4.3.5 Frontotemporal Dementia/Pick
4.3.6 Others
4.4 Progressive Dementia with Neurological Abnormality
4.4.1 Current Trend and Analysis
4.4.2 Market Size and Forecast
4.4.3 Huntington’s Disease
4.4.4 Corticobasal Ganglionic Degeneration
4.4.5 Amyotrophic Lateral Sclerosis(ALS)
CHAPTER 5 TREATMENT FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS MARKET BY GEOGRAPHY: MARKET SIZE AND FORECAST, 2015 – 2024
5.1 Overview
5.2 North America
5.2.1 Current Trend and Analysis
5.2.2 Market Size and Forecast
5.2.3 US
5.2.3.1 Market Size and Forecast
5.2.4 Canada
5.2.4.1 Market Size and Forecast
5.2.5 Mexico
5.2.5.1 Market Size and Forecast
5.3 Europe
5.3.1 Current Trend and Analysis
5.3.2 Market Size and Forecast
5.3.3 UK
5.3.3.1 Market Size and Forecast
5.3.4 Germany
5.3.4.1 Market Size and Forecast
5.3.5 France
5.3.5.1 Market Size and Forecast
5.3.6 Italy
5.3.6.1 Market Size and Forecast
5.3.7 Spain
5.3.7.1 Market Size and Forecast
5.3.8 Others
5.3.8.1 Market Size and Forecast
5.4 Asia-Pacific
5.4.1 Current Trend and Analysis
5.4.2 Market Size and Forecast
5.4.3 Japan
5.4.3.1 Market Size and Forecast
5.4.4 China
5.4.4.1 Market Size and Forecast
5.4.5 India
5.4.5.1 Market Size and Forecast
5.4.6 Others
5.4.6.1 Market Size and Forecast
5.5 RoW
5.5.1 Current Trend and Analysis
5.5.2 Market Size and Forecast
5.5.3 Middle East
5.5.3.1 Market Size and Forecast
5.5.4 South America
5.5.4.1 Market Size and Forecast
5.5.5 Africa
5.5.5.1 Market Size and Forecast
CHAPTER 6 COMPANY PROFILES
6.1 Valeant Pharmaceutical International
6.2 AstraZeneca GmbH
6.3 F. Hoffmann-La Roche, AG
6.4 Abbott Laboratories, Inc.
6.5 Merck & Co., Inc.
6.6 Sanofi S.A.
6.7 Novartis AG
6.8 Bristol-Myers Squibb
6.9 Baxter International, Inc.
6.10 Pfizer, Inc.
1.1 Market Scope
1.2 Report Description
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 In-house Data Modeling
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OUTLINE
3.1 Market Inclination, Trend, Outlook and Viewpoint
3.2 Market Share Analysis: Company’s Competitive Scenario
3.3 Value Chain Analysis
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Impact Analysis
3.4.2 Restraints
3.4.2.1 Impact Analysis
3.4.3 Opportunities
3.5 Porter’s five forces analysis
3.5.1 Factors Impact Analysis
CHAPTER 4 TREATMENT FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS MARKET BY TYPE: MARKET SIZE AND FORECAST, 2015 – 2024
4.1 Overview
4.2 Movement Disorders
4.2.1 Current Trend and Analysis
4.2.2 Market Size and Forecast
4.2.3 Parkinson’s Disease
4.2.4 Progressive Supranuclear Palsy
4.2.4 Multiple System Atrophy
4.2.6 Hallervorden-Spatz Disease
4.2.7 Others
4.3 Progressive Dementia
4.3.1 Current Trend and Analysis
4.3.2 Market Size and Forecast
4.3.3 Alzheimer’s Disease
4.3.4 Lewy Body Dementia
4.3.5 Frontotemporal Dementia/Pick
4.3.6 Others
4.4 Progressive Dementia with Neurological Abnormality
4.4.1 Current Trend and Analysis
4.4.2 Market Size and Forecast
4.4.3 Huntington’s Disease
4.4.4 Corticobasal Ganglionic Degeneration
4.4.5 Amyotrophic Lateral Sclerosis(ALS)
CHAPTER 5 TREATMENT FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS MARKET BY GEOGRAPHY: MARKET SIZE AND FORECAST, 2015 – 2024
5.1 Overview
5.2 North America
5.2.1 Current Trend and Analysis
5.2.2 Market Size and Forecast
5.2.3 US
5.2.3.1 Market Size and Forecast
5.2.4 Canada
5.2.4.1 Market Size and Forecast
5.2.5 Mexico
5.2.5.1 Market Size and Forecast
5.3 Europe
5.3.1 Current Trend and Analysis
5.3.2 Market Size and Forecast
5.3.3 UK
5.3.3.1 Market Size and Forecast
5.3.4 Germany
5.3.4.1 Market Size and Forecast
5.3.5 France
5.3.5.1 Market Size and Forecast
5.3.6 Italy
5.3.6.1 Market Size and Forecast
5.3.7 Spain
5.3.7.1 Market Size and Forecast
5.3.8 Others
5.3.8.1 Market Size and Forecast
5.4 Asia-Pacific
5.4.1 Current Trend and Analysis
5.4.2 Market Size and Forecast
5.4.3 Japan
5.4.3.1 Market Size and Forecast
5.4.4 China
5.4.4.1 Market Size and Forecast
5.4.5 India
5.4.5.1 Market Size and Forecast
5.4.6 Others
5.4.6.1 Market Size and Forecast
5.5 RoW
5.5.1 Current Trend and Analysis
5.5.2 Market Size and Forecast
5.5.3 Middle East
5.5.3.1 Market Size and Forecast
5.5.4 South America
5.5.4.1 Market Size and Forecast
5.5.5 Africa
5.5.5.1 Market Size and Forecast
CHAPTER 6 COMPANY PROFILES
6.1 Valeant Pharmaceutical International
6.2 AstraZeneca GmbH
6.3 F. Hoffmann-La Roche, AG
6.4 Abbott Laboratories, Inc.
6.5 Merck & Co., Inc.
6.6 Sanofi S.A.
6.7 Novartis AG
6.8 Bristol-Myers Squibb
6.9 Baxter International, Inc.
6.10 Pfizer, Inc.
